Redding Post Acute Medicare and Medicaid Location: 1836 Gold Street, Redding, California 96001 Ratings: Phone: (530) 241-6756 |
Marquis Care At Shasta Medicare and Medicaid Location: 3550 Churn Creek Rd., Redding, California 96002 Ratings: Phone: (530) 222-3630 |
Windsor Redding Care Center Medicare and Medicaid Location: 2490 Court Street, Redding, California 96001 Ratings: Phone: (530) 246-0600 |
Crestwood Wellness And Recovery Center Medicaid Location: 3062 Churn Creek Rd., Redding, California 96002 Ratings: Phone: (530) 221-0976 |
Copper Ridge Care Center Medicare and Medicaid Location: 201 Hartnell Avenue, Redding, California 96002 Ratings: Phone: (530) 222-2273 |
Quartz Hill Post Acute Medicare and Medicaid Location: 2120 Benton Drive, Redding, California 96003 Ratings: Phone: (530) 243-6317 |
Vibra Hospital Of Northern California D/p Snf Medicare and Medicaid Location: 2801 Eureka Way, Redding, California 96001 Ratings: Phone: (530) 245-4112 |
Veterans Home Of California - Redding Medicare and Medicaid Location: 3400 Knighton Road, Redding, California 96002 Ratings: Phone: (530) 224-3300 |
News Archive
Over 40 million hours are lost each year due to dental problems and their treatment in the Canadian population, study findings indicate.
HHS has issued a final notice containing an initial set of 26 quality measures for Medicaid-eligible adults. The measures, which cover areas such as prevention, care coordination and chronic disease management, will be used for quality reporting.
Oncolytics Biotech Inc. today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus." The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.
New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling "co-conspirators" in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads.
Biogen Idec and Swedish Orphan Biovitrum today announced that the European Medicines Agency's Pediatric Committee has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein.
› Verified 4 days ago